QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-outperform-on-ocular-therapeutix-lowers-price-target-to-17

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and lowers the price target from $18...

 hc-wainwright--co-reiterates-buy-on-ocular-therapeutix-maintains-14-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $14 price target.

 ocular-therapeutix-to-present-late-breaking-abstract-of-helios-study-at-42nd-asrs-annual-scientific-meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")))), a biopharmaceutical company committed to en...

 piper-sandler-maintains-overweight-on-ocular-therapeutix-maintains-15-price-target

Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price target.

 td-cowen-upgrades-ocular-therapeutix-to-buy-raises-price-target-to-11

TD Cowen analyst Tara Bancroft upgrades Ocular Therapeutix (NASDAQ:OCUL) from Hold to Buy and raises the price target from $...

 piper-sandler-maintains-overweight-on-ocular-therapeutix-maintains-15-price-target

Piper Sandler analyst Joseph Catanzaro maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price ...

 hc-wainwright--co-reiterates-buy-on-ocular-therapeutix-maintains-14-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $14 price target.

 ocular-therapeutix-highlights-axpaxli-sol-1-enrollment-and-plans-repeat-dosing-study-in-wet-amd-announces-48-week-data-from-helios-npdr-study

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7,...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION